OncoMatch/Clinical Trials/NCT04794972
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
Is NCT04794972 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies GNC-039 for recurrent glioma.
Treatment: GNC-039 — In this study, the safety, tolerability and preliminary effectiveness of GNC-039 in patients with relapsed/refractory or metastatic glioma or other solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-039.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Tumor Agnostic
Disease stage
Grade: IIIIV (WHO)
recurrent high-grade glioma (WHO Grade III-IV), or other recurrent/refractory or metastatic solid tumors
Lab requirements
Blood counts
neutrophil absolute count (ANC) ≥1.5×10^9/L, platelet count ≥75×10^9/L, hemoglobin ≥90g/L
Kidney function
creatinine ≤1.5 ULN and creatinine clearance ≥50 mL/min; urinary protein ≤2+ or < 1000mg/24h
Liver function
AST and ALT ≤3.0×ULN; Total bilirubin ≤1.5×ULN (Gilbert's syndrome ≤3×ULN)
Hematological functions ... Renal function ... Liver functions ... Coagulation function: fibrinogen ≥1.5g/L; APTT ≤1.5×ULN; PT ≤1.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04794972 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages